by Steven Ertelt
November 1, 2006
St. Paul, MN (LifeNews.com) — An advance in adult stem cell research could someday lead to treatments for patients with lung diseases. The advance shows that adult stem cells continue to be more ethical and effective than embryonic stem cells, which are only obtained by destroying human life and haven’t yet helped any patients.
Researchers at the University of Minnesota have, for the first time, coaxed umbilical cord blood stem cells to differentiate into a type of lung cell, according to a statement LifeNews.com obtained.
The cord blood cells differentiated into a type of lung cell called type II alveolar cells. These cells are responsible for secreting surfactant, a substance which allows the air sacs in the lungs to remain open, allowing air to move in and out of the sacs.
The cells are also responsible for helping to repair the airway after injury.
"In the future, we may be able to examine cord blood from babies who have lung diseases, such as cystic fibrosis, to do more research to understand how these diseases evolve as well as to develop better medical treatments," said David McKenna, M.D.
He is the assistant professor of lab medicine and pathology and medical director of the Clinical Cell Therapy Lab at the University of Minnesota Medical Center, Fairview.
The discovery is a "step toward developing treatment for various lung diseases" McKenna said.
McKenna’s team will publish their findings in the Nov. 7, 2006, issue of the journal Cytotherapy.
Type II alveolar cells develop late in fetal development, which is why some premature babies are born with underdeveloped lungs. The cells and the air sacs as a whole continue to mature and develop through a child’s first few years of life.
Now the researchers will try to better characterize the cells, so that in the future, the cells could be used as a research tool to better understand lung development and disease. The cells may also be useful as a way to test potential new drugs.
To differentiate the lung cells from the cord blood, McKenna and his team first derived the Multi-Lineage Progenitor Cell from umbilical cord blood. This stem cell, which was first isolated and characterized by BioE, a St. Paul biotech firm, is a precursor cell that can be expanded in culture, then differentiated into different types of tissue representative of all three embryonic lineages, endoderm, mesoderm and ectoderm.
In this series of experiments, McKenna and his group cultured the MLPC and differentiated it into the lung cells, an endoderm-type cell. By testing the cells that grew with various methods, they were able to find cells that exhibited key markers present in type II alveolar cells.
BioE funded the research McKenna’s team conducted.